All News

Having loved ones by your side is right up there in importance with any aspect of healing from cancer.

Researchers found that men with prostate cancer who consumed a diet high in vegetable did not experience clinical benefit; however, overall health benefits were seen.

Mona P is finding hope, life and healing after carcinoma of the pharynx.

Exercise can do so much beyond risk reduction for the person already living with cancer.

Research findings show that rare mutations from donor stem cells can be passed onto patients who receive them, potentially causing health concerns.

One cancer survivor looks at how chemotherapy might have impacted her life in unexpected ways.

From a weight loss drug’s possible cancer risk to a shocking cancer revelation in the death of ESPN reporter Edward Aschoff, here’s what is making headlines in the cancer space this week.

Hope can be a major part of a patient's cancer journey.

How providers communicate medical bills to payers and patients, mandated by the US Centers for Medicare & Medicaid Services, still did not help patients and health care professionals in understanding differences in cost.

With many targeted treatment options for patients with CLL to use upfront, the question arises as to which one is best for the individual.

For my well-being, I am finding a pineapple a day may help in keeping the doctor away.

A brief, multimodal psychosocial intervention for caregivers of patients undergoing hematopoietic stem cell transplantation could improve their quality of life, caregiving burden and anxiety and depression symptoms.

In a first-of-its-kind study, researchers have found an increase in alcohol consumption among cancer survivors that warrants further study and possible alcohol consumption screenings prior to treatment.

The Bladder Cancer Advocacy Network announces it's Bladder Cancer Research Innovation Award.

Researchers from Roswell Park Comprehensive Cancer Center found that the use of supplements, besides a multivitamin, while patients were being treated with chemotherapy increased their risk for breast cancer recurrence or death.

Patients with cancer are acutely aware of how time is finite, and that's ok. They can appreciate the fit of time all the better.

Despite differences in tumors, the addition of CDK 4/6 inhibitors to endocrine therapy showed a benefit in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer compared with endocrine therapy alone.

The three-drug combination of Perjeta and Herceptin with Gemzar shows improved progression-free survival in patients with metastatic breast cancer to advance to a phase 3 trial.

Findings from a recent study supported further evaluation of comparing anti–PD-1 to anti–PD-L1 therapy to help determine treatment options for patients with cancer.

A male breast cancer survivor's take on some promising statistics that show a decline in the cancer death rate in the US, but not for every type of cancer.

FDA has given an accelerated approval to Padcev in the treatment of patients with locally advanced or metastatic urothelial cancer.

Personalized treatments have changed the cancer landscape, and continue to change it for patients with renal cell carcinoma.

One breast cancer and melanoma survivor thinks about the long-term impacts of her cancer diagnosis and the silver linings.

Patients with gastrointestinal stromal tumors have a new targeted therapy that looks to tackle secondary mutations after it showed a strong response rate in the clinic.

Cancer mortality rates have declined significantly since 1991; however, certain cancer types have seen slower progression as of recently because of improved screening.

Researchers found that those who experienced a potentially burdensome end-of-life transition, were more likely not to receive hospice care.

The medication plinabulin is currently being tested in clinical trials to see its benefits in treating chemotherapy-induced neutropenia.

The Bladder Cancer Advocacy Network (BCAN) is pleased to announce two 2020 Young Investigator Awards (YIA), to support the development of outstanding early-career research scientists and clinical cancer research investigators.

This new option may save patients with high-risk non-muscle invasive bladder cancer from having to undergo a radical cystectomy to treat their disease.